Here’s what’s in store for you in today’s issue:
🍄 The future of psychedelics, according to an expert
🍄 A better way to get drunk
🍄 A first-of-its-kind severe anxiety study
🍄 The race for a dementia treatment
🍄 And more.
Kieran, a retired black ops vet who magically cured his neck pain with a wild DMT trip. Kieran talks about being in a constant stress state while serving and how psychedelics help him cope with ongoing PTSD.
This psychedelic makes you feel drunk. Could it be used to treat alcoholism?
5-Methoxy-2-aminoindane (MEAI) is a synthetic molecule that simulates the euphoric feeling of alcohol while reducing the desire to drink.
Pre-clinical studies conducted by Clearmind Medicine Inc. (CMND) show promising evidence that MEAI could treat alcohol use disorder (AUD) and binge drinking. Clinical trials are expected to begin in the second half of 2022.
The company just signed a development and supply agreement with Aragen Life Sciences to manufacture the molecule.
Monash University just got the go-ahead to conduct a first-of-its-kind study!
Yesterday, the Australian university received ethics approval for a triple-blinded, active-placebo-controlled study that will investigate psilocybin-assisted psychotherapy as a treatment for severe Generalized Anxiety Disorder (GAD).
Researchers are looking to recruit 72 patients for the study, which will be conducted in partnership with Incannex Healthcare Ltd (IHL).
The therapists facilitating the study will have the option to undergo their own psilocybin session to better understand what the patients will experience.
Psychedelics clearly have a huge impact on people with mental health issues, but how do they impact people who are already mentally healthy? A new research project at University College London will give us more insights!
After two years of planning, the university is launching the “Understanding Neuroplasticity Induced by Tryptamines” or UNITy Project.
UNITy Project will use fMRI scans, eye-tracking, and experience sampling to understand how the naturally functioning brain responds to various tryptamines (psychedelics that bind to serotonin receptors, such as psilocybin).
The first study will evaluate how DMT affects language processing, sensory processing, and memory in both healthy participants and heavy drinkers, and if neuroplasticity drives the results.
Rick Doblin, a pioneering psychedelic researcher and activist, made some interesting predictions about the future of psychedelics in the US:
Doblin is hopeful that the tremendous impacts on mental health will result in a spiritualized society that “has finally come to the point of embracing global thinking, global humanity, and dealt with economic inequity.”
“We’re all traumatized children running around in adult bodies, and (psychedelic) medicines can help us all,” according to venture capitalist Sanjay Singhal.
That’s why his charity donated $5 million to launch The Nikean Psychedelic Psychotherapy Research Centre at Toronto’s University Health Network (UHN).
The centre will study psilocybin therapy as a treatment for terminally-ill patients, patients with body dysmorphia, families who have lost a child, and grieving caregivers. It will also study 5-MeO-DMT as a PTSD treatment and will train therapists to administer psychedelic therapy.
Singhal, who was diagnosed with bipolar disorder in his 30s, was inspired to fund psychedelic research after a psilocybin trip helped him break down his emotional walls and fix his relationships.
Magic mushrooms may have been the key to this NHL legend’s success.
Mark Messier, the only NHL player to lead two different teams to Stanley Cup championships, said that a magic mushroom trip at age 19 sparked his interest in spirituality and the power of the mind.
“I had no idea the mind was that powerful. Obviously it turned out to be an amazing experience, but more important was the question afterwards: wow, how can I use my mind to empower myself to be a better player, to be a better person, to have more energy, to create a better aura?”
The trip inspired Messier to learn about Eastern philosophies, Buddhism, Indigenous spirituality, and meditation, which had a major influence on him both as a player and a leader.
Cybin (CYBN) is sending therapists on a psychedelic retreat so they can learn how to provide support to frontline healthcare workers.
Clinical trial facilitators will head to a small island in Washington to be trained on Cybin’s new EMBARK therapy model and gain experiential knowledge of psychedelics. The EMBARK model combines aspects of several psychotherapy models and incorporates patients’ spiritual experiences, bodily experiences, and relationships into the healing process.
The retreat will prepare the facilitators for an upcoming clinical trial at the University of Washington that aims to treat healthcare workers suffering from COVID-related distress, depression, anxiety, and PTSD.
Delic Labs of Delic Corp (DELC) is partnering with GT Research Inc. to help mushroom and cannabis producers optimize their products.
Through the deal, Delic Labs will use DNA analysis to evaluate the commercial value of different cannabis and psychedelic mushroom strains based on certain gene traits. The services will help Canadian producers optimize their compounds through genetic engineering to produce more effective plant medicines.
If treatments don’t improve, the number of Americans battling Alzheimer’s is expected to nearly triple by 2050 — reaching $1.1 trillion in care costs.
Fortunately, two more companies joined the race to develop a new treatment using psychedelics!
On Tuesday, MYND Life Sciences (MYND) acquired IP rights from Cava Healthcare Inc. for dementia treatments using psilocybin and other psychedelics. It received the assets in exchange for 450,000 shares at $0.85 each, plus $120,000 and an annual royalty fee.
Silo Pharma Inc. (SILO) also joined the race this week through a sponsored research agreement. The company will work with Columbia University to develop a psychedelic treatment that could halt or reverse Alzheimer’s.
These companies are joining forces to develop unique treatments for a range of debilitating conditions.
Agtech Global International Inc. (AGGL) and KRTL Biotech Inc. are partnering to develop CBD and psilocybin-based medicines to treat conditions like ADHD, pain from cancer, autism, PTSD, depression, and addiction.
The agreement will leverage KRTL’s team of researchers in the US and Korea, where they have already received the Korean equivalent of FDA approval to study the compounds.
Several other companies are supporting the research project including Here To Serve Holding Corp. (HTSC) and Pervasip Corp. (PVSP).
Oct 25 – HAVN Life (HAVN) Announces Departure Of Rick Brar As Director Read more…
Oct 26 – Nova Mentis (NOVA) Earns Psilocybin Orphan Drug Designation in Europe for Fragile X Syndrome Read more…
Oct 27 – Mindset Pharma (MSET) Reports Fiscal Year 2021 Financial Results and Provides Corporate Update Read more…
Oct 27 – PharmaTher (PHRM) Provides Business Update and Releases Financial Results for the First Quarter of Fiscal 2022 Read more…
Oct 28 – Blackhawk Growth’s (BLR) Subsidiary MindBio Therapeutics Appoints Patrick Moher as Advisor Read more…
Oct 28 – Greenbrook TMS (GTMS) Announces Dates For Its Third Quarter 2021 Financial Results Read more…
Oct 28 – MYND Life Sciences (MYND) Announces Appointment of New Director Read more…
Oct 29 – Blackhawk Growth (BLR) Files Fiscal Year Ended June 30, 2021 Financial Reports Read more…
